In conclusion, combination therapy of DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin increased β-cell mass and enhanced β-cell function in an early phase of diabetes in diabetic db/db mice. Here, DPP4 is linked to diabetes mellitus.